NASDAQ:AEZS - Aeterna Zentaris Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.02 (-2.74%)

This chart shows the closing price for AEZS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aeterna Zentaris Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AEZS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AEZS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Aeterna Zentaris in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.71.

This chart shows the closing price for AEZS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Aeterna Zentaris. This rating has held steady since July 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/15/2019HC WainwrightReiterated RatingBuyLow
1/17/2019HC WainwrightReiterated RatingBuyLow
12/20/2018Maxim GroupSet Price TargetBuy$2.00Low
12/20/2018HC WainwrightSet Price TargetBuy$3.00Low
11/14/2018HC WainwrightReiterated RatingBuy$3.00Low
6/15/2018Maxim GroupReiterated RatingBuyLow
5/9/2018HC WainwrightReiterated RatingBuy$3.00High
3/29/2018HC WainwrightReiterated RatingBuy$3.00Low
3/28/2018Maxim GroupSet Price TargetBuy$4.00Medium
1/17/2018Maxim GroupSet Price TargetBuy$4.00High
12/21/2017Maxim GroupSet Price TargetBuy$4.00High
11/29/2017HC WainwrightSet Price TargetBuy$3.00Medium
11/28/2017Maxim GroupSet Price TargetBuy$4.00Low
8/11/2017Maxim GroupSet Price TargetBuy$4.00High
7/19/2017Maxim GroupBoost Price TargetBuy ➝ Buy$2.00 ➝ $4.00High
7/5/2017HC WainwrightSet Price TargetBuy$3.00High
7/1/2017Maxim GroupSet Price TargetBuy$2.00Low
5/10/2017HC WainwrightLower Price TargetBuy ➝ Buy$7.50 ➝ $3.00Low
5/1/2017Maxim GroupSet Price TargetBuy ➝ Buy$11.00 ➝ $2.00High
3/30/2017Maxim GroupReiterated RatingBuy$11.00High
3/16/2017Maxim GroupSet Price TargetBuy$10.00 ➝ $11.00Low
3/8/2017Maxim GroupReiterated RatingBuy$6.00Low
2/14/2017Maxim GroupSet Price TargetBuy$10.00N/A
2/1/2017Maxim GroupSet Price TargetBuy$10.00N/A
1/17/2017Maxim GroupBoost Price TargetBuy$7.00 ➝ $10.00N/A
1/10/2017HC WainwrightReiterated RatingBuy$12.00 ➝ $7.50N/A
1/8/2017Canaccord GenuitySet Price TargetBuy$7.50 ➝ $6.00N/A
11/20/2016HC WainwrightReiterated RatingBuy$12.00N/A
11/11/2016Canaccord GenuityReiterated RatingBuy$9.00 ➝ $7.50N/A
11/10/2016Maxim GroupReiterated RatingBuy$11.00 ➝ $10.00N/A
8/23/2016Canaccord GenuityReiterated RatingBuy$9.00N/A
8/13/2016Maxim GroupReiterated RatingBuy$11.00N/A
8/11/2016HC WainwrightReiterated RatingBuyN/A
8/2/2016Maxim GroupReiterated RatingBuy$11.00N/A
(Data available from 7/24/2016 forward)
Aeterna Zentaris logo
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen name. Aeterna Zentaris Inc. has a license agreement with Julius-Maximilians-University Wuerzburg for the development of an oral prophylactic bacterial vaccine against COVID-19 disease; development, manufacture, and commercialization of targeted immunosuppressive therapeutic proteins for the treatment of neuromyelitis optica spectrum disorder. It also has a license agreement with Consilient Health Ltd. and Novo Nordisk Biopharm Limited for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Read More

Today's Range

Now: $0.71
Low: $0.70
High: $0.73

50 Day Range

MA: $0.87
Low: $0.71
High: $1.12

52 Week Range

Now: $0.71
Low: $0.29
High: $3.62


912,446 shs

Average Volume

1,152,572 shs

Market Capitalization

$86.02 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Aeterna Zentaris?

The following Wall Street analysts have issued stock ratings on Aeterna Zentaris in the last year:
View the latest analyst ratings for AEZS.

What is the current price target for Aeterna Zentaris?

0 Wall Street analysts have set twelve-month price targets for Aeterna Zentaris in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Aeterna Zentaris in the next year.
View the latest price targets for AEZS.

What is the current consensus analyst rating for Aeterna Zentaris?

Aeterna Zentaris currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AEZS.

What other companies compete with Aeterna Zentaris?

How do I contact Aeterna Zentaris' investor relations team?

Aeterna Zentaris' physical mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The biopharmaceutical company's listed phone number is 49-6942-6020 and its investor relations email address is [email protected] The official website for Aeterna Zentaris is